Effect of mild hepatic impairment on the pharmacokinetics of pelacarsen

被引：0
作者：
Yan, Jing-He
Taylor, Amanda
Clough, Timothy
Burmeister-Getz, Elise
Pazdirkova, Marketa
Russo, Cesare
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4135023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4135023
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12) : 1368 - 1372
  • [32] INFLUENCE OF MILD, MODERATE, AND SEVERE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF CLAZOSENTAN
    Bruderer, Shirin
    Tsvitbaum, Nahum
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09) : 1102 - 1102
  • [33] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [34] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [35] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04) : 446 - 452
  • [36] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    Drugs in R&D, 2021, 21 : 375 - 384
  • [37] Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration
    Corey, AE
    Agnew, JR
    King, EC
    Parekh, NJ
    Powell, JH
    Thompson, GA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (05) : 1279 - 1286
  • [38] The Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Tofacitinib, an Orally Active Janus Kinase Inhibitor
    Lawendy, Nervin
    Lamba, Manisha
    Chan, Gary
    Wang, Rong
    Alvey, Christine W.
    Krishnaswami, Sriram
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (06): : 421 - 427
  • [39] The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor
    Nenad Sarapa
    Margaret R. Britto
    Michelle B. Mainka
    Kourosh Parivar
    European Journal of Clinical Pharmacology, 2005, 61 : 247 - 256
  • [40] Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
    Small, David S.
    Zhang, Wei
    Royalty, Jane
    Cannady, Ellen A.
    Downs, Delyn
    Ortega, Demetrio
    Suico, Jeffrey G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (05) : 563 - 572
12345